Sun Sep 14 00:00:00 UTC 2025: Here’s a summary of the article, followed by a rewritten news report:

**Summary:**

A recent study by researchers in India has revealed that the effectiveness of broadly neutralizing antibodies (bNAbs) against HIV varies geographically. The study, comparing HIV strains from India and South Africa, found that Indian strains were more susceptible to some bNAbs, while more resistant to others, compared to South African strains. The findings suggest the need for region-specific HIV prevention and treatment strategies, including tailored antibody cocktails and vaccine design, to combat the virus’s diverse evolution across the globe. The research team has proposed a novel cocktail of three bNAbs called BG18, N6, and PGDM1400, that they predict to be able to neutralise a large proportion of circulating Indian HIV-1 strains with high efficiency.

**News Article:**

**Region-Specific HIV Strategies Key to Combating Viral Diversity, Indian Study Finds**

**CHENNAI, September 14, 2025** – A groundbreaking study by Indian researchers has underscored the critical need for geographically tailored approaches in the fight against HIV. Published in the *Journal of Virology*, the research reveals significant differences in the effectiveness of broadly neutralizing antibodies (bNAbs) against HIV strains circulating in India compared to those in South Africa.

Led by Jayanta Bhattacharya of the Translational Health Science & Technology Institute, Faridabad, the study analyzed the ability of 14 leading bNAbs to neutralize contemporary HIV variants from both countries. The team found that Indian strains were more susceptible to bNAbs targeting the V3 glycan region and the CD4 binding site on the virus, while exhibiting greater resistance to antibodies targeting the V1/V2 apex.

“HIV’s remarkable genetic diversity allows it to evolve differently in different parts of the world,” explained Prof. Bhattacharya. “Therefore, novel treatments and vaccines may not work everywhere in the same way. Regional studies like this one are essential to design therapies that are truly effective on a global scale.”

The researchers even proposed a novel cocktail of three bNAbs called BG18, N6, and PGDM1400, that they predict to be able to neutralise a large proportion of circulating Indian HIV-1 strains with high efficiency.

The findings have significant implications for HIV prevention and treatment strategies. Researchers suggest that passive immunization of high-risk individuals with carefully chosen antibody cocktails, as well as the design of vaccines that elicit similarly broad and potent antibody responses, should be tailored to specific regions. The team also emphasized the importance of ongoing surveillance of viral diversity and antibody effectiveness to ensure the most promising antibody combinations are prioritized for clinical development.

The study, funded by the DBT/Wellcome Trust India Alliance, highlights the challenges posed by HIV’s ability to mutate and adapt, emphasizing the need for continuous innovation and region-specific solutions to combat the global pandemic.

Read More